Hologic, Inc. (NASDAQ:HOLX) Short Interest Update

Hologic, Inc. (NASDAQ:HOLX) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 6,150,000 shares, a growth of 34.0% from the November 15th total of 4,590,000 shares. Currently, 2.8% of the shares of the company are short sold. Based on an average daily volume of 1,590,000 shares, the days-to-cover ratio is presently 3.9 days.

Hologic Stock Down 1.9 %

Hologic stock traded down $1.44 during midday trading on Friday, hitting $73.65. The stock had a trading volume of 2,553,425 shares, compared to its average volume of 1,626,827. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a market cap of $16.71 billion, a P/E ratio of 22.12, a P/E/G ratio of 2.38 and a beta of 0.96. Hologic has a 12 month low of $70.24 and a 12 month high of $84.67. The business has a fifty day moving average price of $79.32 and a 200 day moving average price of $78.59.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the business earned $0.89 earnings per share. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. Research analysts predict that Hologic will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.75% of the company’s stock.

Hedge Funds Weigh In On Hologic

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in Hologic during the 2nd quarter valued at about $25,000. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the third quarter valued at approximately $25,000. Groupama Asset Managment increased its stake in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Sunbelt Securities Inc. bought a new stake in Hologic during the second quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. lifted its position in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, December 10th. Wolfe Research initiated coverage on Hologic in a research report on Friday. They set a “peer perform” rating for the company. Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Mizuho lowered their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $89.50.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.